HMB
Leucine metabolite — preserves muscle in aging, not in young lifters.
What is HMB?
HMB (β-Hydroxy β-Methylbutyrate) is a performance supplement used for preserve muscle in aging. NutriDex grades the human evidence as Mixed. HMB is a metabolite of the amino acid leucine, sold to build muscle and speed recovery. The evidence splits sharply by population. In adults over 50, several meta-analyses find modest but consistent benefits: fat-free mass rises by roughly 0.3–0.4 standardized units (about 0.3 kg of lean mass, up to ~1.5 kg appendicular muscle in the largest 2025 pooling), with small improvements in grip strength and chair-stand time, typically needing 3 g/day for 12+ weeks. In young, resistance-trained adults the picture is different — a 2020 meta-analysis of 11 RCTs found no significant effect on body composition or strength. Benefits appear concentrated in anti-catabolic settings (aging, sarcopenia, bed rest, clinical wasting) rather than muscle-building in healthy athletes. Effect sizes are small and several trials are industry-linked, so expectations should stay measured.
Purported Benefits
Evidence by outcome
The same supplement can be well-proven for one use and unproven for another — here is the human evidence graded outcome by outcome.
| Outcome | Evidence | Effect | Studies |
|---|---|---|---|
| Preserve/increase lean mass in older adultsMultiple meta-analyses in adults >50 show small consistent fat-free-mass gains (SMD ~0.35); needs 3 g/day ≥12 wk. | Moderate | ↑ benefit · small | 3 |
| Build muscle/strength in young trained adults11-RCT meta-analysis in young subjects found no significant effect on fat-free mass or strength during resistance training. | Moderate | — no effect · negligible | 1 |
| Improve strength/physical function (older/sarcopenic)One large pooling found small grip/chair-stand gains; another found no added benefit when HMB is added to exercise. | Mixed | ↔ mixed · small | 2 |
| Added benefit over exercise aloneMeta-analysis: adding HMB to exercise gave no significant extra muscle/strength gain in sarcopenic patients. | Moderate | — no effect · negligible | 1 |